Trial Profile

A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 08 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Enasidenib (Primary) ; Ivosidenib (Primary) ; Antineoplastics; Cytarabine; Daunorubicin
Indications Acute myeloid leukaemia; Myelodysplastic syndromes
Focus Registrational; Therapeutic Use
Acronyms AMLSG 29-18; HOVON 150 AML

02 Oct 2024 Planned End Date changed from 17 Sep 2034 to 19 Sep 2034.
20 Sep 2024 Planned End Date changed from 1 May 2034 to 17 Sep 2034.
20 Sep 2024 Planned primary completion date changed from 1 Oct 2024 to 17 Apr 2027.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com